127 related articles for article (PubMed ID: 34182567)
21. Purine versus non-purine xanthine oxidase inhibitors against cyclophosphamide-induced cardiac and bone marrow toxicity in rats.
El-Sheikh AA; Abdelzaher WY; Gad AA; Abdel-Gaber SA
Hum Exp Toxicol; 2020 Mar; 39(3):249-261. PubMed ID: 31640406
[TBL] [Abstract][Full Text] [Related]
22. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents.
Osada Y; Tsuchimoto M; Fukushima H; Takahashi K; Kondo S; Hasegawa M; Komoriya K
Eur J Pharmacol; 1993 Sep; 241(2-3):183-8. PubMed ID: 8243554
[TBL] [Abstract][Full Text] [Related]
23. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Sánchez-Lozada LG; Tapia E; Soto V; Avila-Casado C; Franco M; Zhao L; Johnson RJ
Nephrol Dial Transplant; 2008 Apr; 23(4):1179-85. PubMed ID: 18048425
[TBL] [Abstract][Full Text] [Related]
24. Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment.
Zhao L; Roche BM; Wessale JL; Kijtawornrat A; Lolly JL; Shemanski D; Hamlin RL
Life Sci; 2008 Feb; 82(9-10):495-502. PubMed ID: 18215719
[TBL] [Abstract][Full Text] [Related]
25. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.
Komoriya K; Osada Y; Hasegawa M; Horiuchi H; Kondo S; Couch RC; Griffin TB
Eur J Pharmacol; 1993 Dec; 250(3):455-60. PubMed ID: 8112406
[TBL] [Abstract][Full Text] [Related]
26. Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.
Fahmi AN; Shehatou GS; Shebl AM; Salem HA
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):819-30. PubMed ID: 27215580
[TBL] [Abstract][Full Text] [Related]
27. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
[TBL] [Abstract][Full Text] [Related]
28. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
[TBL] [Abstract][Full Text] [Related]
29. Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats.
Shirakura T; Nomura J; Matsui C; Kobayashi T; Tamura M; Masuzaki H
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):831-8. PubMed ID: 27198514
[TBL] [Abstract][Full Text] [Related]
30. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
[TBL] [Abstract][Full Text] [Related]
31. Combination of captopril and allopurinol retards fructose-induced metabolic syndrome.
Roncal CA; Reungjui S; Sánchez-Lozada LG; Mu W; Sautin YY; Nakagawa T; Johnson RJ
Am J Nephrol; 2009; 30(5):399-404. PubMed ID: 19696478
[TBL] [Abstract][Full Text] [Related]
32. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
Shen X; Li J; Fu Q; Liu L; Gao X; Chen X; Chen P; Wang C
J Clin Pharm Ther; 2019 Apr; 44(2):318-326. PubMed ID: 30582178
[TBL] [Abstract][Full Text] [Related]
33. Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats.
Kakimoto M; Fujii M; Sato I; Honma K; Nakayama H; Kirihara S; Fukuoka T; Ran S; Hirohata S; Kitamori K; Yamamoto S; Watanabe S
J Appl Biomed; 2023 Jun; 21(2):80-90. PubMed ID: 37376883
[TBL] [Abstract][Full Text] [Related]
34. Diabetes and gout: efficacy and safety of febuxostat and allopurinol.
Becker MA; MacDonald PA; Hunt BJ; Jackson RL
Diabetes Obes Metab; 2013 Nov; 15(11):1049-55. PubMed ID: 23683134
[TBL] [Abstract][Full Text] [Related]
35. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
36. Allopurinol, an inhibitor of xanthine oxidase, reduces uric acid levels and modifies the signs associated with copper deficiency in rats fed fructose.
Fields M; Lewis CG; Lure MD
Free Radic Biol Med; 1996; 20(4):595-600. PubMed ID: 8904301
[TBL] [Abstract][Full Text] [Related]
37. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.
Malik UZ; Hundley NJ; Romero G; Radi R; Freeman BA; Tarpey MM; Kelley EE
Free Radic Biol Med; 2011 Jul; 51(1):179-84. PubMed ID: 21554948
[TBL] [Abstract][Full Text] [Related]
38. Urate-lowering therapy for gout: focus on febuxostat.
Love BL; Barrons R; Veverka A; Snider KM
Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
[TBL] [Abstract][Full Text] [Related]
39. Febuxostat for the treatment of gout.
Bridgeman MB; Chavez B
Expert Opin Pharmacother; 2015 Feb; 16(3):395-8. PubMed ID: 25556668
[TBL] [Abstract][Full Text] [Related]
40. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]